Trends in Financing in Life Sciences: 2024 Updates
By Patrick Nugent
This article is first in a 4-part series reviewing financing solutions for the Life Science sector. As we move into Q2 of 2024, the Fed continues to hold the line on interest rate declines. Capital markets remain tight and for companies in need of growth financing, this is problematic. This…Read More
Read MoreScaling for Growth: Building a Foundation for Your Company’s Next Inflexion Point
By Sandra Gardiner
My career as a finance executive in both biotech and medtech Life Sciences companies has included many assignments where growth was imperative, despite prevailing countercurrents in the market and the challenges this imposed internally: At Lipid Sciences, a privately held biotechnology company pursuing HDL therapies for cardiac and viral applications,…Read More
Read MoreRaising Capital in Life Sciences in 2022-2023: What Works?
By Greg Curhan
Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More
Read More5 Lessons in Cash Management from a CFO
By Anne Samak de la Cerda
When I joined FLG in 2020, I brought 20+ years of experience as a finance executive and CFO to the firm. My current focus is technology businesses, including B2B Software and Consumer platforms as well as Healthcare and Life Sciences. I help teams drive strategies as they plan for growth,…Read More
Read More